A federal multidistrict litigation involving thousands of patients who received a synthetic big toe implant is now one of the most closely watched medical device cases of 2026. The Cartiva implant failure lawsuit has entered a critical phase following the February 2026 centralization of cases into MDL No. 3172 in the Eastern District of Arkansas, with a first bellwether trial projected for August 2026. If you or someone you love received a Cartiva Synthetic Cartilage Implant (SCI) and later experienced implant failure, revision surgery, or permanent joint fusion, this article explains what you need to know about your legal rights and the narrow window available to file a claim.
What Is the Cartiva Implant and Why Is It Failing?
The Cartiva Synthetic Cartilage Implant, approved by the FDA in 2016, was designed and marketed as a motion-preserving alternative to traditional big toe fusion surgery. Made from polyvinyl alcohol hydrogel, the small cylindrical device was implanted directly into the metatarsophalangeal joint of the big toe to relieve pain from hallux rigidus, a degenerative joint condition. Surgeons and patients were drawn to the device because, unlike fusion, it promised preserved range of motion and a faster return to normal activity.
The manufacturer initially claimed a failure rate of approximately 13%. However, post-market data and reports compiled following an FDA Class II recall issued in October 2024 tell a dramatically different story. Real-world studies now indicate that implant failure rates range between 64% and 79% — with some research finding failure rates as high as 79% within just two years of implantation. That represents a failure rate nearly five times higher than what was originally marketed to surgeons and the public. This enormous discrepancy between advertised and actual performance is now central to the Cartiva implant failure lawsuit litigation unfolding in federal court.
The FDA Recall and What It Covers
In October 2024, the FDA issued a Class II recall covering all lots of the Cartiva Synthetic Cartilage Implant manufactured between July 2016 and October 2024. A Class II recall indicates a situation where use of the device may cause temporary or medically reversible adverse health consequences. The scope of this recall is sweeping — it covers essentially every Cartiva SCI implanted in the United States since the device received FDA clearance.
Patients eligible to participate in the Cartiva implant failure lawsuit generally include anyone who received a Cartiva SCI within that July 2016 to October 2024 manufacturing window and subsequently experienced device failure, underwent revision surgery, or was left with a permanent joint fusion. The recall confirmation provides critical evidentiary support for patients pursuing legal claims, as it reflects the FDA’s own determination that the device presented unacceptable risk.
MDL No. 3172: What Centralization Means for Your Case
On February 5, 2026, the U.S. Judicial Panel on Multidistrict Litigation centralized all federally filed Cartiva cases into MDL No. 3172 in the Eastern District of Arkansas. Multidistrict litigation consolidates cases with common factual questions before a single judge to streamline pretrial proceedings, including discovery, depositions, and expert witness coordination. MDL Judge Kristine G. Baker has scheduled an initial organizational hearing for August 26, 2026, at 1:30 p.m. CDT in Little Rock, Arkansas — a significant milestone that signals the litigation is moving forward at pace. This does not mean individual cases lose their identity — each plaintiff retains their own claims and, if a global settlement is not reached, their right to an individual trial. As of mid-2026, no global settlement has been reached. Cartiva has reported settling some individual cases, but broader settlement negotiations remain ongoing. A first bellwether trial is currently projected for August 2026, and its outcome is expected to meaningfully influence the direction of future settlement negotiations across the MDL.
Key Statistics: Marketed Claims vs. Reported Outcomes
The gap between how the Cartiva implant was marketed and how it has actually performed in patients is at the heart of this litigation. Consider the following:
- The manufacturer marketed an approximate 13% failure rate based on clinical trial data.
- Real-world post-market studies now report failure rates between 64% and 79%, with some research documenting failure in as many as 79% of patients within two years of implantation.
- The FDA’s October 2024 Class II recall encompassed every lot manufactured during the device’s entire U.S. commercial lifetime — from July 2016 through October 2024.
- Thousands of patients have already filed claims, and the MDL continues to grow as more affected individuals come forward.
These figures underscore why plaintiffs and their attorneys argue that the manufacturer knew — or should have known — that the device’s real-world performance fell catastrophically short of its marketed claims.
Why Implant Failure Causes Irreversible Harm
When a Cartiva implant fails, the consequences are rarely minor. The most common modes of failure include implant subsidence (sinking into the bone), fragmentation, and rapid cartilage deterioration at the implant site. These failure modes frequently cause severe pain, swelling, and dramatically reduced mobility — often worse than the original hallux rigidus condition the device was meant to treat.
Critically, Cartiva implant failure often forces patients into the very outcome they were trying to avoid: permanent joint fusion surgery. Because the implant can cause bone loss and structural damage at the joint site, revision surgery is frequently more complex and less successful than a primary fusion would have been. Patients are left with permanent limitations on mobility, chronic pain, and — in some cases — the inability to return to work or the physical activities they enjoyed before surgery. These lasting consequences form the foundation of the damages claimed in the Cartiva implant failure lawsuit.
What Plaintiffs Are Alleging Against the Manufacturer
Plaintiffs in MDL No. 3172 are pursuing claims on several overlapping legal theories. While the specific allegations vary by case, the core contentions include:
- Failure to warn: Plaintiffs allege that the manufacturer failed to adequately disclose known risks of implant failure to surgeons and patients, depriving them of the ability to make informed decisions about their care.
- Negligent design: Plaintiffs contend the device was defectively designed and that the manufacturer failed to take reasonable steps to address known design vulnerabilities before or after bringing the product to market.
- Fraudulent misrepresentation: The claimed 13% failure rate, which real-world data has shown to be dramatically understated, forms the basis of claims that the manufacturer made materially false representations to the medical community and patients.
- Breach of warranty: Some plaintiffs allege the manufacturer breached express and implied warranties about the device’s safety and efficacy.
Together, these theories support claims for medical expenses, lost wages, pain and suffering, and — in egregious cases — punitive damages.
Who Should File a Cartiva Implant Failure Lawsuit in 2026
You may have a viable claim if you meet all of the following general criteria:
- You received a Cartiva Synthetic Cartilage Implant at any point between July 2016 and October 2024.
- You subsequently experienced implant failure, were required to undergo revision surgery, or had a permanent joint fusion performed as a result of Cartiva complications.
- You suffered documented damages — including additional medical costs, lost income, or significant pain and impairment — as a result of the device’s failure.
Even if you are not certain whether your implant has failed, unexplained or worsening pain in the implanted joint, swelling, reduced range of motion, or a recommendation from your physician for additional surgery are all warning signs worth discussing with a personal injury attorney. Statutes of limitations vary by state, and waiting can permanently bar your right to recover compensation.
Frequently Asked Questions About the Cartiva Implant Failure Lawsuit
Who qualifies to file a Cartiva implant failure lawsuit in 2026?
In general, patients who received a Cartiva SCI between July 2016 and October 2024 and subsequently experienced device failure, revision surgery, or permanent joint fusion may qualify to file a claim. Qualification depends on individual circumstances, including the nature and extent of your injuries, the documentation available from your treating physicians, and the applicable statute of limitations in your state. An experienced medical device attorney can evaluate your specific situation and advise whether your case meets the threshold for filing.
What compensation can Cartiva lawsuit plaintiffs recover?
Damages in Cartiva implant failure cases typically include past and future medical expenses related to revision surgery and ongoing treatment, lost wages and diminished earning capacity, pain and suffering, and loss of enjoyment of life. In cases involving particularly egregious conduct by the manufacturer, courts may also award punitive damages. As of mid-2026, projected settlement values range from approximately $25,000 to $350,000 or more, depending on the severity of complications, the need for additional surgeries, and the extent of long-term impairment. No global settlement has yet been finalized, and the outcome of the anticipated August 2026 bellwether trial is expected to play a significant role in shaping future settlement values across the MDL.
What is MDL No. 3172 and how does it affect individual cases?
MDL No. 3172 is the federal multidistrict litigation established in February 2026 in the Eastern District of Arkansas to consolidate all federally filed Cartiva implant failure cases before a single judge. The MDL streamlines pretrial proceedings — including discovery and expert witness coordination — but does not eliminate individual cases. Each plaintiff’s case retains its own identity. If the litigation does not resolve through a global settlement, individual cases can be remanded to their home districts for trial. MDL Judge Kristine G. Baker has scheduled an initial organizational hearing for August 26, 2026, in Little Rock, Arkansas, reflecting the court’s active management of this growing litigation.
Why is the Cartiva failure rate so much higher than what was marketed?
The manufacturer’s claimed 13% failure rate was based on clinical trial data that critics argue was too limited in scope, duration, and patient population to accurately predict real-world outcomes. Post-market surveillance and independent studies have since documented failure rates between 64% and 79% — with some research finding that as many as 79% of patients experienced implant failure within two years of implantation. Plaintiffs allege that the manufacturer either knew of these risks and failed to disclose them or failed to conduct adequate post-market surveillance that would have revealed the device’s true performance. This discrepancy is among the central issues in the ongoing litigation.
How long do I have to file a Cartiva implant failure lawsuit?
The deadline to file a Cartiva implant failure lawsuit depends on the statute of limitations in your state, which typically ranges from one to four years from the date of injury or discovery of injury. Because the applicable deadline varies by jurisdiction and because some states apply discovery rules that can either extend or shorten the filing window, it is critical to consult with an attorney as soon as possible. Missing the statute of limitations deadline will permanently bar your right to seek compensation, regardless of the merits of your claim. With MDL proceedings active and a bellwether trial projected for August 2026, the litigation is moving quickly — and so should you.
Thomas B. Harrison is a personal injury legal consultant with extensive experience connecting injury victims with qualified attorneys across the United States. He specializes in helping people understand when they need legal representation and how to find the right personal injury attorney for their specific situation. Thomas is not an attorney and the information he provides is for educational purposes only.